{"fetched":"2026-09-21","previousFetched":"2026-09-17","keepDays":90,"changes":[{"detected":"2026-09-21","drugId":"polatuzumab-vedotin","nct":"NCT04594798","title":"A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL","phases":["PHASE2"],"sponsor":"University of Rochester","primaryCompletion":"2027-07-31","kind":"primary-completion","from":"2026-07-31","to":"2027-07-31"},{"detected":"2026-09-21","drugId":"tiragolumab","nct":"NCT04665856","title":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2023-08-31","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-21","drugId":"thyrotropin-alfa","nct":"NCT05128383","title":"Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids","phases":["PHASE2"],"sponsor":"Beth Israel Deaconess Medical Center","primaryCompletion":"2025-05-19","kind":"results-posted"},{"detected":"2026-09-21","drugId":"trifluridine-tipiracil","nct":"NCT06039202","title":"CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer","phases":["PHASE2"],"sponsor":"Holy Stone Healthcare Co., Ltd","primaryCompletion":"2030-10","kind":"status","from":"UNKNOWN","to":"SUSPENDED"},{"detected":"2026-09-21","drugId":"trifluridine-tipiracil","nct":"NCT06039202","title":"CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer","phases":["PHASE2"],"sponsor":"Holy Stone Healthcare Co., Ltd","primaryCompletion":"2030-10","kind":"primary-completion","from":"2025-02","to":"2030-10"},{"detected":"2026-09-21","drugId":"intismeran-autogene","nct":"NCT06077760","title":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2030-06-25","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-21","drugId":"izalontamab-brengitecan","nct":"NCT06855771","title":"A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)","phases":["PHASE2"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2028-12-29","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"enfortumab-vedotin","nct":"NCT06906822","title":"PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients","phases":["PHASE2"],"sponsor":"Grupo Español Multidisciplinar de Melanoma","primaryCompletion":"2027-06","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-21","drugId":"iparomlimab-tuvonralimab","nct":"NCT06954116","title":"Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence","phases":["PHASE2"],"sponsor":"Tongji Hospital","primaryCompletion":"2028-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"tarlatamab","nct":"NCT07061080","title":"Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab","phases":["PHASE2"],"sponsor":"Grupo Espanol de Tumores Neuroendocrinos","primaryCompletion":"2026-09-03","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"TERMINATED"},{"detected":"2026-09-21","drugId":"tarlatamab","nct":"NCT07061080","title":"Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab","phases":["PHASE2"],"sponsor":"Grupo Espanol de Tumores Neuroendocrinos","primaryCompletion":"2026-09-03","kind":"primary-completion","from":"2028-12","to":"2026-09-03"},{"detected":"2026-09-21","drugId":"romiplostim","nct":"NCT07421167","title":"A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)","phases":["PHASE2"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2029-01-18","kind":"primary-completion","from":"2028-05-09","to":"2029-01-18"},{"detected":"2026-09-21","drugId":"sacituzumab-tirumotecan","nct":"NCT07438626","title":"Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-06-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"pucotenlimab","nct":"NCT07497919","title":"A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2029-05-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"pluvicto","nct":"NCT07650240","title":"Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2030-12-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"isatuximab","nct":"NCT07652905","title":"CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia","phases":["PHASE2"],"sponsor":"Institute of Hematology & Blood Diseases Hospital, China","primaryCompletion":"2029-06-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"alpelisib","nct":"NCT07679269","title":"Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.","phases":["PHASE2"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2032-03-23","kind":"primary-completion","from":"2031-06-27","to":"2032-03-23"},{"detected":"2026-09-21","drugId":"nalirifox","nct":"NCT07827053","title":"Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer","phases":["PHASE2"],"sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","primaryCompletion":"2029-09-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-21","drugId":"glecirasib","nct":"NCT07827261","title":"A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","primaryCompletion":"2028-12","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-21","drugId":"giredestrant","nct":"NCT07827573","title":"A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2028-11-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-21","drugId":"vepugratinib","nct":"NCT07827612","title":"A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer","phases":["PHASE2"],"sponsor":"Eli Lilly and Company","primaryCompletion":"2028-07","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-21","drugId":"f182112","nct":"NCT07828522","title":"F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma","phases":["PHASE2"],"sponsor":"Institute of Hematology & Blood Diseases Hospital, China","primaryCompletion":"2027-10-09","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"vemurafenib","nct":"NCT01709292","title":"Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-09-30","kind":"primary-completion","from":"2026-09-30","to":"2028-09-30"},{"detected":"2026-09-17","drugId":"pralatrexate","nct":"NCT01947140","title":"Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies","phases":["PHASE1","PHASE2"],"sponsor":"Jennifer Amengual","primaryCompletion":"2022-09-01","kind":"status","from":"COMPLETED","to":"TERMINATED"},{"detected":"2026-09-17","drugId":"pralatrexate","nct":"NCT01947140","title":"Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies","phases":["PHASE1","PHASE2"],"sponsor":"Jennifer Amengual","primaryCompletion":"2022-09-01","kind":"results-posted"},{"detected":"2026-09-17","drugId":"flutamide","nct":"NCT03070886","title":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","phases":["PHASE2","PHASE3"],"sponsor":"NRG Oncology","primaryCompletion":"2025-10-31","kind":"status","from":"COMPLETED","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"olaparib","nct":"NCT04191135","title":"Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)","phases":["PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2022-12-15","kind":"status","from":"COMPLETED","to":"TERMINATED"},{"detected":"2026-09-17","drugId":"dinutuximab","nct":"NCT04211675","title":"NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab","phases":["PHASE1","PHASE2"],"sponsor":"Nationwide Children's Hospital","primaryCompletion":"2026-12","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"fedratinib","nct":"NCT04282187","title":"Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms","phases":["PHASE2"],"sponsor":"University of Washington","primaryCompletion":"2027-11-11","kind":"primary-completion","from":"2026-11-11","to":"2027-11-11"},{"detected":"2026-09-17","drugId":"tiragolumab","nct":"NCT04543617","title":"A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2026-07-22","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-17","drugId":"tiragolumab","nct":"NCT04543617","title":"A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2026-07-22","kind":"primary-completion","from":"2027-03-31","to":"2026-07-22"},{"detected":"2026-09-17","drugId":"dabrafenib","nct":"NCT04544111","title":"PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2027-09-02","kind":"primary-completion","from":"2026-09-02","to":"2027-09-02"},{"detected":"2026-09-17","drugId":"sonrotoclax","nct":"NCT04771130","title":"A Study of BGB-11417 in Participants With Myeloid Malignancies","phases":["PHASE1","PHASE2"],"sponsor":"BeOne Medicines","primaryCompletion":"2028-08-31","kind":"primary-completion","from":"2028-02-08","to":"2028-08-31"},{"detected":"2026-09-17","drugId":"glofitamab","nct":"NCT04889716","title":"CAR-T Followed by Bispecific Antibodies","phases":["PHASE2"],"sponsor":"Abramson Cancer Center at Penn Medicine","primaryCompletion":"2027-12-31","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"abemaciclib","nct":"NCT04921904","title":"Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca","phases":["PHASE1","PHASE2"],"sponsor":"Baylor Research Institute","primaryCompletion":"2024-12-31","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-17","drugId":"abemaciclib","nct":"NCT04921904","title":"Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca","phases":["PHASE1","PHASE2"],"sponsor":"Baylor Research Institute","primaryCompletion":"2024-12-31","kind":"results-posted"},{"detected":"2026-09-17","drugId":"darolutamide","nct":"NCT05059236","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","phases":["PHASE2"],"sponsor":"Bayer","primaryCompletion":"2025-05-30","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-17","drugId":"darolutamide","nct":"NCT05059236","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","phases":["PHASE2"],"sponsor":"Bayer","primaryCompletion":"2025-05-30","kind":"results-posted"},{"detected":"2026-09-17","drugId":"foundationone-cdx","nct":"NCT05197322","title":"NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer","phases":["PHASE2"],"sponsor":"University College, London","primaryCompletion":"2029-11-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"foundationone-cdx","nct":"NCT05197322","title":"NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer","phases":["PHASE2"],"sponsor":"University College, London","primaryCompletion":"2029-11-01","kind":"primary-completion","from":"2026-07-31","to":"2029-11-01"},{"detected":"2026-09-17","drugId":"fulvestrant","nct":"NCT05262400","title":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2027-02-26","kind":"primary-completion","from":"2026-08-23","to":"2027-02-26"},{"detected":"2026-09-17","drugId":"dinutuximab","nct":"NCT05421897","title":"Rapid Administration Pilot for Infusing Dinutuximab","phases":["PHASE2"],"sponsor":"Children's Hospital Los Angeles","primaryCompletion":"2028-11","kind":"new-study","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"trifluridine-tipiracil","nct":"NCT05438459","title":"GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites","phases":["PHASE1","PHASE2"],"sponsor":"Kyushu University","primaryCompletion":"2032-03-31","kind":"primary-completion","from":"2028-12-31","to":"2032-03-31"},{"detected":"2026-09-17","drugId":"lorigerlimab","nct":"NCT05475171","title":"Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-06-30","kind":"status","from":"SUSPENDED","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"olaparib","nct":"NCT05524935","title":"Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma","phases":["PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2027-07","kind":"primary-completion","from":"2026-07","to":"2027-07"},{"detected":"2026-09-17","drugId":"giredestrant","nct":"NCT05634499","title":"A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer","phases":["PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2026-08-25","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-17","drugId":"giredestrant","nct":"NCT05634499","title":"A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer","phases":["PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2026-08-25","kind":"primary-completion","from":"2026-08-28","to":"2026-08-25"},{"detected":"2026-09-17","drugId":"apalutamide","nct":"NCT05751941","title":"Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer","phases":["PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2026-07-04","kind":"primary-completion","from":"2026-07","to":"2026-07-04"},{"detected":"2026-09-17","drugId":"axicabtagene-ciloleucel","nct":"NCT05757219","title":"Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy","phases":["PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2027-02","kind":"primary-completion","from":"2026-06-20","to":"2027-02"},{"detected":"2026-09-17","drugId":"dalpiciclib","nct":"NCT05759572","title":"Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2026-07-21","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"dalpiciclib","nct":"NCT05759572","title":"Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2026-07-21","kind":"primary-completion","from":"2025-11-01","to":"2026-07-21"},{"detected":"2026-09-17","drugId":"treosulfan","nct":"NCT05807932","title":"Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","phases":["PHASE1","PHASE2"],"sponsor":"Heinrich-Heine University, Duesseldorf","primaryCompletion":"2029-04-30","kind":"primary-completion","from":"2026-01-31","to":"2029-04-30"},{"detected":"2026-09-17","drugId":"fruquintinib","nct":"NCT05831891","title":"Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma","phases":["PHASE2"],"sponsor":"RenJi Hospital","primaryCompletion":"2027-10-22","kind":"primary-completion","from":"2026-07-31","to":"2027-10-22"},{"detected":"2026-09-17","drugId":"nalirifox","nct":"NCT05851924","title":"A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2027-09-01","kind":"primary-completion","from":"2026-09-01","to":"2027-09-01"},{"detected":"2026-09-17","drugId":"tiragolumab","nct":"NCT05908786","title":"A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma","phases":["PHASE1","PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2025-08-27","kind":"status","from":"COMPLETED","to":"TERMINATED"},{"detected":"2026-09-17","drugId":"tiragolumab","nct":"NCT05908786","title":"A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma","phases":["PHASE1","PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2025-08-27","kind":"results-posted"},{"detected":"2026-09-17","drugId":"gemtuzumab-ozogamicin","nct":"NCT05955261","title":"A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia","phases":["PHASE2"],"sponsor":"St. Jude Children's Research Hospital","primaryCompletion":"2026-12","kind":"status","from":"SUSPENDED","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"foundationone-cdx","nct":"NCT06065748","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2028-04-20","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"foundationone-cdx","nct":"NCT06065748","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2028-04-20","kind":"primary-completion","from":"2027-02-19","to":"2028-04-20"},{"detected":"2026-09-17","drugId":"arlocabtagene-autoleucel","nct":"NCT06297226","title":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","phases":["PHASE2"],"sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","primaryCompletion":"2026-07-31","kind":"primary-completion","from":"2027-06-30","to":"2026-07-31"},{"detected":"2026-09-17","drugId":"enfortumab-vedotin","nct":"NCT06394570","title":"Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer","phases":["PHASE1","PHASE2"],"sponsor":"University of Texas Southwestern Medical Center","primaryCompletion":"2028-09-30","kind":"primary-completion","from":"2026-07-01","to":"2028-09-30"},{"detected":"2026-09-17","drugId":"bosutinib","nct":"NCT06423911","title":"Study of Olverembatinib (HQP1351) in Patients With CML-CP","phases":["PHASE3"],"sponsor":"Ascentage Pharma Group Inc.","primaryCompletion":"2027-06-30","kind":"primary-completion","from":"2025-12","to":"2027-06-30"},{"detected":"2026-09-17","drugId":"dalpiciclib","nct":"NCT06495515","title":"Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer","phases":["PHASE2"],"sponsor":"Tianjin Medical University Cancer Institute and Hospital","primaryCompletion":"2025-07-30","kind":"status","from":"UNKNOWN","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"tarlatamab","nct":"NCT06816394","title":"Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)","phases":["PHASE2"],"sponsor":"National Taiwan University Hospital","primaryCompletion":"2027-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"zolbetuximab","nct":"NCT06901531","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","phases":["PHASE3"],"sponsor":"Astellas Pharma Global Development, Inc.","primaryCompletion":"2028-09-30","kind":"primary-completion","from":"2027-03-31","to":"2028-09-30"},{"detected":"2026-09-17","drugId":"cetuximab-sarotalocan","nct":"NCT06943664","title":"Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Roswell Park Cancer Institute","primaryCompletion":"2027-05-01","kind":"status","from":"NOT_YET_RECRUITING","to":"WITHDRAWN"},{"detected":"2026-09-17","drugId":"carfilzomib","nct":"NCT06948084","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2028-02-28","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"tarlatamab","nct":"NCT07061080","title":"Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab","phases":["PHASE2"],"sponsor":"Grupo Espanol de Tumores Neuroendocrinos","primaryCompletion":"2028-12","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"aglatimagene-besadenovec","nct":"NCT07332000","title":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","phases":["PHASE2"],"sponsor":"Candel Therapeutics, Inc.","primaryCompletion":"2027-02","kind":"primary-completion","from":"2026-08","to":"2027-02"},{"detected":"2026-09-17","drugId":"tqb6411","nct":"NCT07367516","title":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","primaryCompletion":"2027-02","kind":"primary-completion","from":"2026-09","to":"2027-02"},{"detected":"2026-09-17","drugId":"naxitamab","nct":"NCT07537400","title":"Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5","phases":["PHASE2"],"sponsor":"Shaare Zedek Medical Center","primaryCompletion":"2028-06","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"botensilimab","nct":"NCT07551596","title":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2029-08-28","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"botensilimab","nct":"NCT07551596","title":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2029-08-28","kind":"primary-completion","from":"2026-09-30","to":"2029-08-28"},{"detected":"2026-09-17","drugId":"pivekimab-sunirine","nct":"NCT07581002","title":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","phases":["PHASE2","PHASE3"],"sponsor":"AbbVie","primaryCompletion":"2032-06","kind":"primary-completion","from":"2032-05","to":"2032-06"},{"detected":"2026-09-17","drugId":"nalirifox","nct":"NCT07622771","title":"Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial","phases":["PHASE2"],"sponsor":"Sun Yat-sen University","primaryCompletion":"2028-06-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"lurbinectedin","nct":"NCT07625644","title":"BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)","phases":["PHASE3"],"sponsor":"SystImmune Inc.","primaryCompletion":"2030-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"enfortumab-vedotin","nct":"NCT07667335","title":"Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Fred Hutchinson Cancer Center","primaryCompletion":"2029-07-16","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"nintedanib","nct":"NCT07679893","title":"Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis","phases":["PHASE2"],"sponsor":"Mannkind Corporation","primaryCompletion":"2027-12-30","kind":"primary-completion","from":"2028-01-30","to":"2027-12-30"},{"detected":"2026-09-17","drugId":"sacituzumab-tirumotecan","nct":"NCT07718854","title":"Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer","phases":["PHASE2"],"sponsor":"Tufts Medical Center","primaryCompletion":"2036-09","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"sacituzumab-tirumotecan","nct":"NCT07718854","title":"Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer","phases":["PHASE2"],"sponsor":"Tufts Medical Center","primaryCompletion":"2036-09","kind":"primary-completion","from":"2032-03","to":"2036-09"},{"detected":"2026-09-17","drugId":"palifermin","nct":"NCT07775313","title":"Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM","phases":["PHASE1","PHASE2"],"sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","primaryCompletion":"2031-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"ENROLLING_BY_INVITATION"},{"detected":"2026-09-17","drugId":"ql1706","nct":"NCT07776080","title":"Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus","phases":["PHASE2"],"sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","primaryCompletion":"2027-10-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"azd5335","nct":"NCT07816666","title":"Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2028-09-26","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"trastuzumab-rezetecan","nct":"NCT07817654","title":"Trastuzumab Combined With Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Receptor 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy Failure","phases":["PHASE2"],"sponsor":"Henan Cancer Hospital","primaryCompletion":"2027-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"envafolimab","nct":"NCT07818304","title":"SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC","phases":["PHASE2"],"sponsor":"The First People's Hospital of Lianyungang","primaryCompletion":"2028-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"sctb35","nct":"NCT07819188","title":"SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"Sinocelltech Ltd.","primaryCompletion":"2028-09-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"epcoritamab","nct":"NCT07819214","title":"Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI","phases":["PHASE2"],"sponsor":"University of California, Irvine","primaryCompletion":"2028-10","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"sacituzumab-tirumotecan","nct":"NCT07819578","title":"Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC","phases":["PHASE2"],"sponsor":"Shaodong Hong","primaryCompletion":"2028-12-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"daraxonrasib","nct":"NCT07819838","title":"Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations","phases":["PHASE1","PHASE2"],"sponsor":"Children's Oncology Group","primaryCompletion":"2032-04-09","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"megestrol-progestins","nct":"NCT07820358","title":"Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer","phases":["PHASE2"],"sponsor":"The Methodist Hospital Research Institute","primaryCompletion":"2028-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"hs-20089","nct":"NCT07821606","title":"Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer","phases":["PHASE3"],"sponsor":"Hansoh BioMedical R&D Company","primaryCompletion":"2029-12-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"telisotuzumab-adizutecan","nct":"NCT07821684","title":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"AbbVie","primaryCompletion":"2031-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"enfortumab-vedotin","nct":"NCT07822373","title":"A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer","phases":["PHASE2"],"sponsor":"University of Utah","primaryCompletion":"2034-11","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"sacituzumab-tirumotecan","nct":"NCT07823270","title":"Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"Hebei Medical University Fourth Hospital","primaryCompletion":"2028-12","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"inca33890","nct":"NCT07823322","title":"A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy","phases":["PHASE2"],"sponsor":"Incyte Corporation","primaryCompletion":"2029-05-14","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"ql2107","nct":"NCT07823491","title":"Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall","phases":["PHASE3"],"sponsor":"Ohio State University Comprehensive Cancer Center","primaryCompletion":"2028-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"radioactive-iodine","nct":"NCT07823686","title":"Tracheal Replacement Using A Cryopreserved Aortic Allograft For R0 Resection In Locally Advanced Thyroid Cancer (TRITON 02 Tracheal Replacement In ThyrOid caNcer)","phases":["PHASE2"],"sponsor":"Assistance Publique - Hôpitaux de Paris","primaryCompletion":"2030-08-27","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"hpv-quadrivalent-vaccine","nct":"NCT07824310","title":"Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children","phases":["PHASE3"],"sponsor":"PT Bio Farma","primaryCompletion":"2026-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"hlx22","nct":"NCT07824869","title":"A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients","phases":["PHASE2"],"sponsor":"Shanghai Henlius Biotech","primaryCompletion":"2028-03-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"hs-20093","nct":"NCT07824882","title":"A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations","phases":["PHASE2"],"sponsor":"Hansoh BioMedical R&D Company","primaryCompletion":"2028-03-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"avutometinib-defactinib","nct":"NCT07824960","title":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma","phases":["PHASE1","PHASE2"],"sponsor":"University of Virginia","primaryCompletion":"2029-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"cevostamab","nct":"NCT07825064","title":"Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma","phases":["PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2029-04-13","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"datopotamab-deruxtecan","nct":"NCT07825753","title":"Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2027-09-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"dalpiciclib","nct":"NCT07826052","title":"Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2031-09-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-11","drugId":"dabrafenib","nct":"NCT04201457","title":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration","phases":["PHASE1","PHASE2"],"sponsor":"Pediatric Brain Tumor Consortium","primaryCompletion":"2026-10-01","kind":"primary-completion","from":"2026-03-31","to":"2026-10-01"},{"detected":"2026-09-11","drugId":"ipilimumab","nct":"NCT04464759","title":"A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma","phases":["PHASE1","PHASE2"],"sponsor":"Ravi Amaravadi, MD","primaryCompletion":"2026-11-13","kind":"primary-completion","from":"2026-07-31","to":"2026-11-13"},{"detected":"2026-09-11","drugId":"cabozantinib","nct":"NCT04820179","title":"Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer","phases":["PHASE2"],"sponsor":"University of Arizona","primaryCompletion":"2026-02-20","kind":"results-posted"},{"detected":"2026-09-11","drugId":"imlunestrant","nct":"NCT04923542","title":"SR & Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases","phases":["PHASE1","PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2026-11-05","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-11","drugId":"sacituzumab-govitecan","nct":"NCT05186974","title":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","phases":["PHASE2"],"sponsor":"Gilead Sciences","primaryCompletion":"2027-03","kind":"primary-completion","from":"2026-09","to":"2027-03"},{"detected":"2026-09-11","drugId":"epcoritamab","nct":"NCT05201248","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"Genmab","primaryCompletion":"2026-09","kind":"primary-completion","from":"2025-04","to":"2026-09"},{"detected":"2026-09-11","drugId":"lurbinectedin","nct":"NCT05229588","title":"Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations","phases":["PHASE2"],"sponsor":"HonorHealth Research Institute","primaryCompletion":"2025-08-04","kind":"results-posted"},{"detected":"2026-09-11","drugId":"inavolisib","nct":"NCT05306041","title":"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer","phases":["PHASE2"],"sponsor":"GBG Forschungs GmbH","primaryCompletion":"2027-01","kind":"primary-completion","from":"2026-10","to":"2027-01"},{"detected":"2026-09-11","drugId":"amivantamab","nct":"NCT05845450","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","phases":["PHASE2"],"sponsor":"Gruppo Oncologico del Nord-Ovest","primaryCompletion":"2027-05","kind":"primary-completion","from":"2026-05","to":"2027-05"},{"detected":"2026-09-11","drugId":"revumenib","nct":"NCT06229912","title":"A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-12-01","kind":"primary-completion","from":"2026-12-01","to":"2028-12-01"},{"detected":"2026-09-11","drugId":"mosunetuzumab","nct":"NCT06492837","title":"Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients","phases":["PHASE2"],"sponsor":"Fondazione Italiana Linfomi - ETS","primaryCompletion":"2028-09-15","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-11","drugId":"sotorasib","nct":"NCT06582771","title":"A Study of Sotorasib in People With Non-Small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2027-08","kind":"primary-completion","from":"2026-08","to":"2027-08"},{"detected":"2026-09-11","drugId":"relatlimab-nivolumab","nct":"NCT06708949","title":"A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-12-15","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-11","drugId":"relatlimab-nivolumab","nct":"NCT06708949","title":"A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-12-15","kind":"primary-completion","from":"2026-12-15","to":"2028-12-15"},{"detected":"2026-09-11","drugId":"lisocabtagene-maraleucel","nct":"NCT07098364","title":"ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"Fred Hutchinson Cancer Center","primaryCompletion":"2030-10-04","kind":"status","from":"RECRUITING","to":"SUSPENDED"},{"detected":"2026-09-11","drugId":"degarelix","nct":"NCT07335796","title":"A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2030-01-09","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-11","drugId":"penpulimab","nct":"NCT07381075","title":"A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"West China Hospital","primaryCompletion":"2028-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-11","drugId":"penpulimab","nct":"NCT07381075","title":"A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"West China Hospital","primaryCompletion":"2028-12-31","kind":"primary-completion","from":"2028-10-01","to":"2028-12-31"},{"detected":"2026-09-11","drugId":"bicalutamide","nct":"NCT07593079","title":"Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer","phases":["PHASE2"],"sponsor":"Washington University School of Medicine","primaryCompletion":"2027-11-14","kind":"primary-completion","from":"2027-08-14","to":"2027-11-14"},{"detected":"2026-09-11","drugId":"olomorasib","nct":"NCT07814417","title":"A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation","phases":["PHASE2"],"sponsor":"Eli Lilly and Company","primaryCompletion":"2028-11","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-11","drugId":"sacituzumab-tirumotecan","nct":"NCT07815197","title":"Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer","phases":["PHASE2"],"sponsor":"Latin American Cooperative Oncology Group","primaryCompletion":"2028-03","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-11","drugId":"dalpiciclib","nct":"NCT07815522","title":"Abiraterone With Dalpiciclib in Salivary Gland Carcinoma","phases":["PHASE2"],"sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","primaryCompletion":"2028-10-01","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-11","drugId":"enfortumab-vedotin","nct":"NCT07815665","title":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","phases":["PHASE2","PHASE3"],"sponsor":"Summit Therapeutics","primaryCompletion":"2030-10-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-11","drugId":"crizotinib","nct":"NCT07816380","title":"A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 Versus Crizotinib in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"Guangzhou JOYO Pharma Co., Ltd","primaryCompletion":"2028-12-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-10","drugId":"inotuzumab-ozogamicin","nct":"NCT03104491","title":"Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia","phases":["PHASE1","PHASE2"],"sponsor":"Leland Metheny","primaryCompletion":"2026-11","kind":"primary-completion","from":"2025-11","to":"2026-11"},{"detected":"2026-09-10","drugId":"cpx-351","nct":"NCT04061239","title":"Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML","phases":["PHASE2"],"sponsor":"GWT-TUD GmbH","primaryCompletion":"2026-08-07","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-09-10","drugId":"cpx-351","nct":"NCT04061239","title":"Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML","phases":["PHASE2"],"sponsor":"GWT-TUD GmbH","primaryCompletion":"2026-08-07","kind":"primary-completion","from":"2026-03","to":"2026-08-07"},{"detected":"2026-09-10","drugId":"tiragolumab","nct":"NCT04958811","title":"Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC","phases":["PHASE2"],"sponsor":"Georgetown University","primaryCompletion":"2026-11","kind":"primary-completion","from":"2026-07","to":"2026-11"},{"detected":"2026-09-10","drugId":"megestrol-progestins","nct":"NCT05316935","title":"GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients","phases":["PHASE2","PHASE3"],"sponsor":"Xiaojun Chen","primaryCompletion":"2028-03-30","kind":"primary-completion","from":"2026-03-30","to":"2028-03-30"},{"detected":"2026-09-10","drugId":"luspatercept","nct":"NCT05664737","title":"A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia","phases":["PHASE2"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2027-07-16","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-10","drugId":"megestrol-progestins","nct":"NCT06379113","title":"GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients","phases":["PHASE2","PHASE3"],"sponsor":"Xiaojun Chen","primaryCompletion":"2028-03-30","kind":"primary-completion","from":"2026-03-30","to":"2028-03-30"},{"detected":"2026-09-10","drugId":"talquetamab","nct":"NCT06572605","title":"External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease","phases":["PHASE1","PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2030-01-18","kind":"status","from":"RECRUITING","to":"SUSPENDED"},{"detected":"2026-09-10","drugId":"serplulimab","nct":"NCT06576921","title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","phases":["PHASE2"],"sponsor":"Xijing Hospital","primaryCompletion":"2026-08-10","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-10","drugId":"serplulimab","nct":"NCT06576921","title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","phases":["PHASE2"],"sponsor":"Xijing Hospital","primaryCompletion":"2026-08-10","kind":"primary-completion","from":"2026-05-31","to":"2026-08-10"},{"detected":"2026-09-10","drugId":"ivonescimab","nct":"NCT07602855","title":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","phases":["PHASE1","PHASE2"],"sponsor":"GlaxoSmithKline","primaryCompletion":"2029-06-21","kind":"primary-completion","from":"2029-07-05","to":"2029-06-21"},{"detected":"2026-09-10","drugId":"izalontamab-brengitecan","nct":"NCT07640789","title":"A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)","phases":["PHASE3"],"sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","primaryCompletion":"2030-12","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-10","drugId":"sacituzumab-tirumotecan","nct":"NCT07811752","title":"Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer","phases":["PHASE2"],"sponsor":"Shanghai Chest Hospital","primaryCompletion":"2027-12-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-10","drugId":"sonrotoclax","nct":"NCT07812246","title":"Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial","phases":["PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2028-08-13","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-10","drugId":"pirtobrutinib","nct":"NCT07812493","title":"Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement","phases":["PHASE2"],"sponsor":"Pengpeng Xu","primaryCompletion":"2028-09-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-10","drugId":"epcoritamab","nct":"NCT07814001","title":"Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy","phases":["PHASE2"],"sponsor":"The Lymphoma Academic Research Organisation","primaryCompletion":"2028-07","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-09","drugId":"trastuzumab-emtansine","nct":"NCT02675829","title":"Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2026-09-04","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-09","drugId":"trastuzumab-emtansine","nct":"NCT02675829","title":"Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2026-09-04","kind":"primary-completion","from":"2027-02","to":"2026-09-04"},{"detected":"2026-09-09","drugId":"optune","nct":"NCT02847559","title":"Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma","phases":["PHASE2"],"sponsor":"Northwestern University","primaryCompletion":"2025-08-11","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-09-09","drugId":"optune","nct":"NCT02847559","title":"Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma","phases":["PHASE2"],"sponsor":"Northwestern University","primaryCompletion":"2025-08-11","kind":"primary-completion","from":"2026-09","to":"2025-08-11"},{"detected":"2026-09-09","drugId":"encorafenib","nct":"NCT03803553","title":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","phases":["PHASE3"],"sponsor":"Massachusetts General Hospital","primaryCompletion":"2026-12","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"relatlimab-nivolumab","nct":"NCT04080804","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","phases":["PHASE2"],"sponsor":"Dan Zandberg","primaryCompletion":"2026-04-13","kind":"primary-completion","from":"2027-10-01","to":"2026-04-13"},{"detected":"2026-09-09","drugId":"brentuximab-vedotin","nct":"NCT05039073","title":"Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors","phases":["PHASE2"],"sponsor":"Emory University","primaryCompletion":"2027-11-30","kind":"primary-completion","from":"2026-11-30","to":"2027-11-30"},{"detected":"2026-09-09","drugId":"autogene-cevumeran","nct":"NCT05968326","title":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","phases":["PHASE2"],"sponsor":"Genentech, Inc.","primaryCompletion":"2031-01-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"encorafenib","nct":"NCT06578559","title":"Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC","phases":["PHASE2"],"sponsor":"Gruppo Oncologico del Nord-Ovest","primaryCompletion":"2026-05-12","kind":"primary-completion","from":"2026-08-01","to":"2026-05-12"},{"detected":"2026-09-09","drugId":"lutathera","nct":"NCT06955169","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","phases":["PHASE2"],"sponsor":"RTOG Foundation, Inc.","primaryCompletion":"2029-08","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-09","drugId":"disitamab-vedotin","nct":"NCT06966453","title":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2027-10-25","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"tarlatamab","nct":"NCT07005128","title":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)","phases":["PHASE3"],"sponsor":"Amgen","primaryCompletion":"2029-01-04","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"tarlatamab","nct":"NCT07016230","title":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)","phases":["PHASE2"],"sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","primaryCompletion":"2027-05-18","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-09","drugId":"tarlatamab","nct":"NCT07016230","title":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)","phases":["PHASE2"],"sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","primaryCompletion":"2027-05-18","kind":"primary-completion","from":"2026-10-18","to":"2027-05-18"}]}